Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.
Status:
Completed
Trial end date:
2017-10-27
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare safety and efficacy of stem cell mobilization using
G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in multiple
myeloma patients.
Phase:
Phase 3
Details
Lead Sponsor:
Maria Sklodowska-Curie Institute - Oncology Center Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology